Business Development

Founded in 2009 by two young Fred Hutch researchers — computational biologist Harlan Robins and molecular biologist and geneticist Chris Carlson — Adaptive Biotechnologies has quickly become a leader in high-throughput DNA sequencing of immune system T cells and B cells for research and diagnostic purposes. In 2018, Adaptive announced a partnership with Microsoft Research to combine its sequencing technology with machine learning and artificial intelligence, with the goal of mapping the entire human immune system and eventually developing a universal blood test to detect any diseases a person’s body may be fighting.

Juno Therapeutics was founded in 2013 as a collaboration between Fred Hutch, Memorial Sloan Kettering Cancer Center and Seattle Children’s Research Institute, combining cutting-edge immunotherapy expertise from all three institutions. With $120 million in Series A private investment funding, Juno was one of the largest biotech launches in history. Juno is now Bristol Myers Squibb, where teams are working to develop innovative T-cell therapies to treat a broad range of cancers. Building on Juno's transformative research, Bristol Myers Squibb launched its first commercially approved CAR T-cell therapy in February 2021.

Founded in 2014, Faraday Pharmaceuticals is advancing pioneering research from Mark Roth’s lab at Fred Hutch on how salts can temporarily shift a person’s metabolism to protect against injury when blood rushes back to a damaged area after circulation has stopped — such as after a heart attack. Roth, a 2007 MacArthur Foundation “genius” grant recipient, has served as president of the company and a member of the board of directors since its founding.